Navigation Links
Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints
Date:4/8/2008

Results Published in the Journal of Clinical Dentistry Demonstrate Significant Cavity-Fighting Efficacy of New Fluoride-Free BasicMints(TM)

ROSLYN HEIGHTS, N.Y. and STONY BROOK, N.Y., April 8, 2008 /PRNewswire/ -- Ortek Therapeutics, Inc. and Stony Brook University announced today that new data published in the most recent issue of the Journal of Clinical Dentistry demonstrates the effects of a new chewable mint in preventing cavities in children. This investigational product, called BasicMints(TM), contains CaviStat(R), an innovative, fluoride-free, cavity fighting complex. CaviStat is designed to mimic the profound cavity fighting benefits of saliva, by neutralizing harmful plaque acids and simultaneously promoting the remineralization of the tooth structure. The results show the children who were administered BasicMints had 62 percent fewer cavities in their molars after one year compared to children in the placebo group.

CaviStat was developed, clinically tested and patented by researchers in the Department of Oral Biology and Pathology at the State University of New York at Stony Brook and exclusively licensed to Ortek. Ortek is planning to submit an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) later this year. BasicMints are not currently approved for use in the U.S. All of the components of CaviStat are naturally present in the human body.

Cavities are the most prevalent disease in children, with almost half of all children having a cavity by second grade and 80 percent having a cavity by the time they graduate from high school. Approximately 90 percent of cavities in the teeth of children occur in the biting surfaces of the back teeth. By chewing BasicMints and packing CaviStat into these vulnerable surfaces, protection is focused where most cavities form.

"Cavities affect the quality of life for millions of children every year by causing them pain, to miss school days and cost billions of dollars to repair annually," said Dr. Israel Kleinberg, the lead researcher and inventor of the CaviStat technology and Distinguished Professor and Founding Chairman of the Department of Oral Biology and Pathology at the State University of New York at Stony Brook. "This study shows for the first time that this new fluoride-free, cavity-fighting tool has the potential to significantly improve the oral health of children."

The study published in the March 2008 issue of the Journal of Clinical Dentistry showed that after six months, children (N=96) who took BasicMints with CaviStat twice a day had 68.3 percent fewer cavities than the placebo group. After 12 months those children had 61.7 percent fewer cavities as compared to the placebo group (N=99) (P<0.001) in all of the molars studied (first permanent molars, some erupting premolars, second molars and deciduous molars). In the first permanent molars, some early erupting premolars and second molars, the children who were in the BasicMints study group had 75.6 percent less cavities after six months (P<0.001) and 50.7 percent less cavities after 12 months (P<0.001), as compared to the placebo group. Additionally, the children in the BasicMints study group had 76.2 percent less cavities in the deciduous molars after six months and 74.8 percent less cavities after 12 months, as compared to the placebo controls.

"We are truly excited about the results demonstrated by BasicMints in this new study and are looking forward to working with the U.S. Food and Drug Administration to bring this new cavity-prevention technology to market," said Mitchell Goldberg, President, Ortek Therapeutics, Inc., the makers of BasicMints.

About the Study

The study published in the March issue of Journal of Clinical Dentistry was a one-year, double-blind, placebo controlled study that demonstrates that sugarless mints containing the fluoride-free CaviStat technology were able to inhibit both the onset and progression of cavities in 10 and 11 year-old children in Venezuela. The study participants took four mints daily, two in the morning after brushing their teeth and before eating breakfast and two in the evening after brushing their teeth, before going to bed. There were 200 children enrolled in the study and 195 who finished the one-year study with complete data. Ninety-six children were in the study group and received the BasicMints with CaviStat and 99 children were in the placebo group and received the sugarless mints without CaviStat.

The BasicMints study was funded by Ortek Therapeutics, Inc.

About BasicMints and CaviStat

BasicMints is a new experimental drug in pre-clinical testing designed to prevent the formation of tooth decay. This soft, chewable, sugarless, mint flavored tablet contains CaviStat, Ortek's innovative, fluoride-free, cavity fighting complex. BasicMints are designed to be dissolved and chewed into the biting and approximating surfaces of the back teeth. These vulnerable surfaces account for approximately 90 percent of cavities in children.

CaviStat is a new innovative, fluoride-free, cavity fighting complex that is designed to mimic and integrate the powerful alkali producing, acid neutralizing and remineralizing benefits of saliva. CaviStat was designed to counter the formation of dental cavities by simultaneously inhibiting the two fundamental processes known for more than a hundred years to be responsible for cavity development, namely, acid generation by bacterial fermentation of appropriate carbohydrate substrates and solubilization of tooth mineral by the acid generated. CaviStat contains the amino acid arginine, which when metabolized by certain plaque bacteria, results in elevation of dental plaque pH by alkali generation. It also contains bicarbonate, an important buffer in saliva; and calcium carbonate, a poorly soluble calcium salt. The latter provides a source of calcium to prevent tooth solubilization, and under appropriate conditions, favors pH elevation and enhanced tooth mineralization.

About Ortek Therapeutics, Inc.

Ortek Therapeutics, Inc., headquartered in Roslyn Heights, NY, is a privately held, specialty pharmaceutical company primarily engaged in developing and commercializing proprietary products for the prevention and detection of tooth decay. Ortek's goal is to develop a continuous stream of new products that will improve the quality of life for people everywhere.

About Stony Brook University School of Dental Medicine

The primary mission of the Stony Brook University School of Dental Medicine is to educate caring and skilled dentists who are well prepared to enter private practice or enter graduate or specialty training programs. The Department of Oral Biology & Pathology is one of seven academic departments in the School of Dental Medicine. Research efforts through faculty are intended to advance oral and systemic health in collaboration with medical colleagues, industry, private foundations, and governmental agencies. The School also serves the profession with its continuing education programs and promotes the mission of Stony Brook University and the Health Sciences Center through collaborative efforts in teaching, research and service.


'/>"/>
SOURCE Ortek Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Breast-Feeding Doesnt Contribute to Cavities
2. Parents can Help Young Superheroes Battle Cavities on Halloween Night
3. Overweight kids have fewer cavities, new study shows
4. Children of depressed moms do better when dad is involved, SLU researcher finds
5. High pollution linked to poor lung function growth in children in Mexico City
6. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
7. Obese Children Miss More School Days
8. Ultra-Runner to Run 63 Marathons in 63 Days for Children with Incurable Disease
9. Psoriasis Cure Now offers Back to School Resources for Parents of Children with Psoriasis
10. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
11. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... 27, 2017 , ... From May 21-23, hearing healthcare professionals gained a competitive ... at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , As EarQ’s ... hearing healthcare providers to help them stay ahead in the industry. At the event, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, ... 30th and 31st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of ... the healthiest seniors are located in the Midwest. With the average cost of healthcare ... people are concerned with both the quality and affordability of where they live. An ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original ... discounted crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget ... a fidget toy to the market that was made of superior quality and wouldn’t ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled ... a new, informational blog post on insurance options. If a Bay Area patient has ... help save time and money. Visiting an in-network provider for a second opinion can ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... N.Y. , May 22, 2017  Lilac ... treatment Gene-Eden-VIR/Novirin, announces the launch of a ... English, the results of a clinical study that ... year treatment with Gene-Eden-VIR/Novirin in individuals suffering from ... to note that there are no other treatments ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, ... industry leader in noninvasive pain relief, was awarded a ... magazine. Baxter was recognized at the MM&M Top ... New York City on May 10, 2017. ... the biopharma industry go "beyond the pill."  ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology: